Cost advantages concentrated in higher OOP tiers: only 15% of all prescriptions were cheaper, but MCCPDC undercut insurance for ~82% of fills when OOP exceeded $15. Therapeutic areas with frequent triple-digit generic cost-sharing included oncology,

Though generic drugs represent more than 90% of dispensed prescriptions, generic drug manufacturers continue to face pressure from drug distributors, pharmacy benefit managers, and competitors. But this reality doesn’t necessarily mean investors should ...

The Food and Drug Administration’s (FDA or Agency) final rule on Additional Conditions for Nonprescription Use (ACNU) paves the way for some drugs that are currently available only with a prescription to switch to OTC where a patient satisfies certain ...

“Generic drugs provide additional treatment options which are generally more affordable for patients. Today’s approval underscores the FDA’s continued commitment to advancing patient access to safe, effective and high-quality generic drug products,” Dr. Iilun Murphy, the director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research, said in a statement.

Generic drug manufacturers are facing increasing pressure from drug distributors, pharmacy benefit managers, and Indian competitors, leading to downward trends in generic drug prices. Which firms are positioned to succeed in this market environment?

April sales data shows indigenous obesity and diabetes drug, led by Torrent, are expanding access without denting demand for branded versions.

Poorer countries bear a greater burden of metabolic diseases but even with cheaper medicines, pharma companies will make access difficult.

Since his second term started, President Trump has introduced a flurry of initiatives aimed at taming the excesses of the pharmaceutical industry.